Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation
BB106 is formulated for subcutaneous delivery, which could make ketamine-based pain management a viable alternative to opioids.
News provided by
Share this article
Share this article
SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat. No. 10,973,780, describing pharmaceutical formulations and treatment methods including the company's BB106 ketamine therapy. Bexson believes the new utilities identified in this patent will allow safety, comfort and pharmacokinetics that greatly improve ketamine administration for multiple routes of administration, including subcutaneous.